How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its extensive supply chain?

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

Following the report, several state legislators – including Carr, K.C. Ohaebosim, Henry Helgerson, Susan Estes, Angela ...

Loblaw divests 42 Wellwise by Shoppers stores to Verillium Health Care, focusing on pharmacy growth as the healthcare brand ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

A harbor seal and a Chilean flamingo at the Lincoln Park Zoo died as a result of avian influenza last week, zoo officials ...

Medical supply chain experts have previously said Trump’s proposed tariffs would likely cause the price of imported drugs to go up. Still, there are several factors at play when it comes to ...

Wells Fargo analyst Larry Biegelsen has maintained their neutral stance on JNJ stock, giving a Hold rating yesterday.Stay Ahead of the ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

To Luis Roman, vice president of MedTech Supply Chain at Johnson & Johnson, the digital journey represents more than just improving supply chain operations. “For us, digital innovation is viewed as an ...

A potential investor said to Temie Giwa-Tubosun—an African woman and founder of LifeBank, which provides life-saving medical supplies ... workforce (Christman, 2022, Supply & Demand Chain Executive).